Sanofi-Aventis is a global healthcare company dedicated to improving health and well-being through the development and production of a wide range of pharmaceutical products and vaccines. With a strong focus on research and innovation, the company operates in various therapeutic areas, including diabetes, oncology, cardiovascular disease, central nervous system disorders, immunology, and rare diseases. Sanofi-Aventis also emphasizes the importance of vaccines in disease prevention and offers a portfolio that addresses public health needs. The company strives to enhance patients' quality of life by providing effective treatments and advancing healthcare solutions worldwide. Read More
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response rates and reduced disease flares.
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year.
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with a promising bispecific antibody.
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
Investors are keeping a close eye on SANOFI-ADR (NASDAQ:SNY) as it boasts an impressive technical rating of 8 out of 10, signaling a possible breakout.
